References
1. Pui CH, Yang JJ, Hunger SP, et al. Childhood Acute Lymphoblastic
Leukemia: Progress Through Collaboration. J Clin Oncol.2015;33(27):2938-2948.
2. Bhatia S, Landier W, Shangguan M, et al. Nonadherence to oral
mercaptopurine and risk of relapse in Hispanic and non-Hispanic white
children with acute lymphoblastic leukemia: a report from the children’s
oncology group. J Clin Oncol. 2012;30(17):2094-2101.
3. Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE. Prognostic
importance of 6-mercaptopurine dose intensity in acute lymphoblastic
leukemia. Blood. 1999;93(9):2817-2823.
4. Denton CC, Rawlins YA, Oberley MJ, Bhojwani D, Orgel E. Predictors of
hepatotoxicity and pancreatitis in children and adolescents with acute
lymphoblastic leukemia treated according to contemporary regimens.Pediatr Blood Cancer. 2018;65(3).
5. Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular
studies of thiopurine methyltransferase. Drug Metab Dispos.2001;29(4 Pt 2):601-605.
6. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J
Clin Pharmacol. 1992;43(4):329-339.
7. Bostrom B, Erdmann G. Cellular pharmacology of 6-mercaptopurine in
acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol.1993;15(1):80-86.
8. Maelachuri S, Gandrud L, Bostrom B. The association between fasting
hypoglycemia and methylated mercaptopurine metabolites in children with
acute lymphoblastic leukemia. Pediatr Blood Cancer.2014;61(6):1003-1006.
9. Adam de Beaumais T, Fakhoury M, Medard Y, et al. Determinants of
mercaptopurine toxicity in paediatric acute lymphoblastic leukemia
maintenance therapy. Br J Clin Pharmacol. 2011;71(4):575-584.
10. Nygaard U, Toft N, Schmiegelow K. Methylated metabolites of
6-mercaptopurine are associated with hepatotoxicity. Clin
Pharmacol Ther. 2004;75(4):274-281.
11. Blaker PA, Arenas-Hernandez M, Smith MA, et al. Mechanism of
allopurinol induced TPMT inhibition. Biochem Pharmacol.2013;86(4):539-547.
12. Roberts RL, Gearry RB, Barclay ML. Allopurinol-thiopurine
combination therapy in inflammatory bowel disease: are there genetic
clues to this puzzle? Pharmacogenomics. 2010;11(11):1505-1508.
13. Zimm S, Collins JM, O’Neill D, Chabner BA, Poplack DG. Inhibition of
first-pass metabolism in cancer chemotherapy: interaction of
6-mercaptopurine and allopurinol. Clin Pharmacol Ther.1983;34(6):810-817.
14. Brackett J, Schafer ES, Leung DH, Bernhardt MB. Use of allopurinol
in children with acute lymphoblastic leukemia to reduce skewed
thiopurine metabolism. Pediatr Blood Cancer.2014;61(6):1114-1117.
15. Giamanco NM, Cunningham BS, Klein LS, Parekh DS, Warwick AB, Lieuw
K. Allopurinol Use During Maintenance Therapy for Acute Lymphoblastic
Leukemia Avoids Mercaptopurine-related Hepatotoxicity. J Pediatr
Hematol Oncol. 2016;38(2):147-151.
16. Zerra P, Bergsagel J, Keller FG, Lew G, Pauly M. Maintenance
Treatment With Low-Dose Mercaptopurine in Combination With Allopurinol
in Children With Acute Lymphoblastic Leukemia and Mercaptopurine-Induced
Pancreatitis. Pediatr Blood Cancer. 2016;63(4):712-715.
17. Zhang M, Bostrom B. Allopurinol reverses mercaptopurine-induced
hypoglycemia in patients with acute lymphoblastic leukemia.F1000Res. 2019;8:176.
18. Rahhal RM, Bishop WP. Initial clinical experience with
allopurinol-thiopurine combination therapy in pediatric inflammatory
bowel disease. Inflamm Bowel Dis. 2008;14(12):1678-1682.
19. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and
metabolite measurement for 6-mercaptopurine therapy in inflammatory
bowel disease. Gastroenterology. 2000;118(4):705-713.
20. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles
provide a biochemical explanation for 6-MP resistance in patients with
inflammatory bowel disease. Gastroenterology.2002;122(4):904-915.
21. Castrejon I, Toledano E, Rosario MP, Loza E, Pérez-Ruiz F, Carmona
L. Safety of allopurinol compared with other urate-lowering drugs in
patients with gout: a systematic review and meta-analysis.Rheumatology international. 2015;35(7):1127-1137.
22. Asadov C, Aliyeva G, Mustafayeva K. Thiopurine S-Methyltransferase
as a Pharmacogenetic Biomarker: Significance of Testing and Review of
Major Methods. Cardiovasc Hematol Agents Med Chem.2017;15(1):23-30.
23. Cooper SC, Ford LT, Berg JD, Lewis MJ. Ethnic variation of
thiopurine S-methyltransferase activity: a large, prospective population
study. Pharmacogenomics. 2008;9(3):303-309.
24. Cunningham B, Krishnamurthy J, Deutsch J, Flora MN, Lieuw K. 360
Elucidating the Mechanism of 6-Mercaptopurine Induced Hepatotoxicity and
How Combination with Allopurinol Eliminates the Hepatotoxicity.Gastroenterology. 2016;150(4):S1030.